FDA Approves Denali's Hunter Syndrome Drug, Signaling Shift in Rare Disease Policy
The FDA has granted accelerated approval to Denali Therapeutics' drug for Hunter syndrome, marking a significant step forward. This approval occurs amid tighter regulatory scrutiny on rare disease treatments, signaling a potential shift in policy and industry practices.
· 71d ago
